Ibrexafungerp

Major

Ibrexafungerp Haloperidol Increased haloperidol exposure and an increased risk of haloperidol-related adverse events, including QTc interval prolongation Details Ibrexafungerp Idelalisib Zydelig Increased ibrexafungerp exposure Details Ibrexafungerp Indinavir Increased ibrexafungerp exposure Details Ibrexafungerp Itraconazole Sporanox Increased ibrexafungerp exposure Details Ibrexafungerp Ivosidenib Tibsovo Decreased ibrexafungerp exposure and loss of antifungal efficacy Details Ibrexafungerp Ketoconazole Extina Increased ibrexafungerp exposure Details Ibrexafungerp Larotrectinib Increased sensitive CYP3A4 substrate exposure and increase in the incidence or severity of adverse reactions Details Ibrexafungerp Lefamulin Xenleta Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions and increased sensitive CYP3A4 substrate ex... Details Ibrexafungerp Lemborexant Dayvigo Increased lemborexant exposure and an increased risk of lemborexant-related adverse reactions. Details Ibrexafungerp Lenacapavir Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Ibrexafungerp Letermovir Prevymis Increased CYP3A substrate exposure Details Ibrexafungerp Lomitapide Increased lomitapide exposure Details Ibrexafungerp Lonafarnib Zokinvy Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Ibrexafungerp Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Ibrexafungerp Lopinavir Increased ibrexafungerp exposure Details Ibrexafungerp Lorlatinib Lorbrena Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Lumacaftor Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Mavorixafor Xolremdi Increased mavorixafor exposure and an increased risk of mavorixafor-related adverse effects Details Ibrexafungerp Methylergonovine Methergine Increased methylergonovine exposure Details Ibrexafungerp Mifepristone Korlym Increased CYP3A4 substrate exposure and an increased miFEPRIStone exposure Details Ibrexafungerp Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Ibrexafungerp Mitotane Lysodren Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Modafinil Provigil Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Morphine Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Ibrexafungerp Morphine Sulfate Liposome Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Ibrexafungerp Nafcillin Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Nefazodone Increased ibrexafungerp exposure Details Ibrexafungerp Nelfinavir Viracept Increased ibrexafungerp exposure Details Ibrexafungerp Nifedipine Adalat® Increased NIFEdipine exposure Details Ibrexafungerp Olutasidenib Rezlidhia Reduced sensitive CYP3A substrate exposure Details Ibrexafungerp Omaveloxolone Skyclarys Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Ibrexafungerp Phenobarbital Fidoquel Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Phenytoin Dilantin Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Pimozide Increased pimozide exposure Details Ibrexafungerp Pirtobrutinib Jaypirca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-related adverse effects Details Ibrexafungerp Posaconazole Noxafil Increased ibrexafungerp exposure and an increased posaconazole exposure Details Ibrexafungerp Primidone Mysoline Decreased ibrexafungerp plasma concentrations Details Ibrexafungerp Ranolazine Aspruzyo Increased ranolazine exposure and an increased CYP3A4 substrate exposure Details Ibrexafungerp Relacorilant Lifyorli Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Ibrexafungerp Repotrectinib Augtyro Increased repotrectinib exposure and an increased risk of repotrectinib-related adverse effects Details